Regulation of Bmal1 activity SIRT1 regulates PER protein degradation by inhibiting transcriptional activity of the BMAL1:CLOCK heterodimer in a circadian manner through
deacetylation. The degradation of PER proteins prevents the formation of the large protein complex, and thus disinhibits the transcriptional activity of the BMAL1:CLOCK
heterodimer. The CRY protein is also signaled for degradation by poly-ubiquitination from the
FBXL3 protein resulting in the disinhibition of BMAL1:CLOCK
heterodimer activity. Several
posttranslational modifications of BMAL1 dictate the timing of the CLOCK/BMAL1 feedback loops.
Phosphorylation of BMAL1 targets it for ubiquitination and degradation, as well as deubiquitination and stabilization.
Acetylation of BMAL1 recruits CRY1 to suppress the
transactivation of CLOCK/BMAL1. The
sumoylation of BMAL1 by small
ubiquitin-related modifier 3 signals its
ubiquitination in the nucleus, leading to
transactivation of the CLOCK/BMAL1 heterodimer. CLOCK/BMAL1 transactivation, is activated by phosphorylation by casein kinase 1ε and inhibited by phosphorylation by MAPK. Phosphorylation by
CK2α regulates BMAL1 intracellular localization and phosphorylation by
GSK3B controls BMAL1 stability and primes it for
ubiquitination. In 2004,
Rora was discovered to be an activator of
Bmal1 transcription within the suprachiasmatic nucleus (SCN), regulated by its core clock. Rora was found to be required for normal
Bmal1 expression as well as consolidation of daily locomotor activity.
Species distribution Along with mammals such as humans and mice,
orthologs of the
Arntl gene are also found in fish (AF144690.1), birds (
Arntl), reptiles, amphibians (XI.2098), and
Drosophila (
Cycle, which encodes a protein lacking the homologous C-terminal domain, but still dimerizes with the CLOCK protein). Unlike mammalian
Arntl, circadian regulated, the
Drosophila Cycle (gene) is constitutively expressed. In humans, three transcript variants encoding two different isoforms have been found for this gene. Recent phenotype data also suggest this gene and its partner Clock play a role in the regulation of glucose
homeostasis and metabolism, which can lead to
hypoinsulinaemia or diabetes when disrupted. In regards to other functions, another study shows that the CLOCK/BMAL1 complex upregulates human
LDLR promoter activity, suggesting the
Arntl gene also plays a role in
cholesterol homeostasis. Furthermore, BMAL1 has been shown to influence excitability and seizure threshold. In addition,
BMAL1 gene expression, along with that of other core clock genes, were discovered to be lower in patients with
bipolar disorder, suggesting a problem with circadian function in these patients. An SNP in
Bmal1 was identified as having a link with bipolar disorder.
Arntl,
Npas2, and
Per2 have also been associated with
seasonal affective disorder in humans. Alzheimer's patients have different rhythms in BMAL1 methylation suggesting that its misregulation contributes to cognitive deficits. Research has also shown that BMAL1 and other clock genes drive the expression of clock-controlled genes that are associated with Autism Spectrum Disorder (ASD). Lastly,
BMAL1 has been identified through functional
genetic screening as a putative regulator of the
p53 tumor suppressor pathway suggesting potential involvement in the circadian rhythms exhibited by cancer cells. In animal models of
multiple sclerosis (MS), namely the
experimental autoimmune encephalomyelitis (EAE) model, it has been shown that daily circadian rhythms can play an important role in disease pathology. Inducing EAE through the active immunization of mice with
myelin oligodendrocyte glycoprotein (MOG) peptide during the rest phase is more efficient in comparison to that during the active phase. Disparity in EAE induction is critically dependent on BMAL1 expression in
T cells and
myeloid cells. T cell or myeloid-specific deletion of
Bmal1 has been shown to cause more severe pathology and is sufficient to abolish the rest vs. active induction effect. == Structure ==